A rapid pro-hemostatic approach to overcome direct oral anticoagulants

Nature Medicine

Volumn 22, Issue 8, 2016, Pages 924-932

  Thalji, Nabil K ^a,b   Ivanciu, Lacramioara ^a,b   Davidson, Robert ^a   Gimotty, Phyllis A ^b   Krishnaswamy, Sriram ^a,b   Camire, Rodney M ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDOTE; ANTITHROMBIN; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A I16L; DABIGATRAN; ENOXAPARIN; FONDAPARINUX; GD BLOOD CLOTTING FACTOR 10A S195A; HEMOSTATIC AGENT; RIVAROXABAN; THROMBIN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; CAROTID ARTERY OBSTRUCTION; CATALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HEMOSTASIS; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE; ANIMAL; BLOOD CLOTTING; CHEMISTRY; DRUG EFFECTS; IN VITRO STUDY; THROMBOELASTOGRAPHY;

ANIMALS; ANTIDOTES; BLOOD COAGULATION; FACTOR XA; FACTOR XA INHIBITORS; HEMOSTASIS; HUMANS; IN VITRO TECHNIQUES; MICE; RIVAROXABAN; THROMBELASTOGRAPHY;

EID: 84979544134     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4149     Document Type: Article

References (64)

1. Ansell, J. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133, 160S-198S (2008).
2. Yeh, C.H., Hogg, K. & Weitz, J.I. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler. Thromb. Vasc. Biol. 35, 1056-1065 (2015).
3. Perzborn, E. et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 3, 514-521 (2005).
4. Pinto, D.J. et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 50, 5339-5356 (2007).
5. Furugohri, T. et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J. Thromb. Haemost. 6, 1542-1549 (2008).
6. Di Nisio, M., Middeldorp, S. & Büller, H.R. Direct thrombin inhibitors. N. Engl. J. Med. 353, 1028-1040 (2005).
7. Büller, H.R. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med. 369, 1406-1415 (2013).
8. Granger, C.B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992 (2011).
9. Lassen, M.R. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776-2786 (2008).
10. Connolly, S.J. et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806-817 (2011).
11. Connolly, S.J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
12. Bauersachs, R. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363, 2499-2510 (2010).
13. Dentali, F. et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 126, 2381-2391 (2012).
14. Fox, B.D., Kahn, S.R., Langleben, D., Eisenberg, M.J. & Shimony, A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomized controlled trials. Br. Med. J. 345, e7498 (2012).
15. Siegal, D.M. & Cuker, A. Reversal of target-specific oral anticoagulants. Drug Discov. Today 19, 1465-1470 (2014).
16. Crowther, M. & Crowther, M.A. Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler. Thromb. Vasc. Biol. 35, 1736-1745 (2015).
17. Ansell, J.E. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. J. Thromb. Thrombolysis 41, 248-252 (2016).
18. Husted, S., Verheugt, F.W. & Comuth, W.J. Reversal strategies for NOACs: state of development, possible clinical applications and future perspectives. Drug Saf. 39, 5-13 (2016).
19. Schiele, F. et al. A specific antidote for dabigatran: functional and structural characterization. Blood 121, 3554-3562 (2013).
20. Glund, S. et al. Safety, tolerability and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomized, placebo-controlled, double-blind phase 1 trial. Lancet 386, 680-690 (2015).
21. Lu, G. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 19, 446-451 (2013).
22. Ansell, J.E. et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N. Engl. J. Med. 371, 2141-2142 (2014).
23. Eerenberg, E.S. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124, 1573-1579 (2011).
24. Perzborn, E., Heitmeier, S., Laux, V. & Buchmüller, A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb. Res. 133, 671-681 (2014).
25. Herrmann, R. et al. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb. Haemost. 111, 989-995 (2014).
26. Perzborn, E. et al. Reversal of rivaroxaban anticoagulation by hemostatic agents in rats and primates. Thromb. Haemost. 110, 162-172 (2013).
27. Godier, A. et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116, 94-102 (2012).
28. Vandana, M. et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Blood 122, 3636-3636 (2013).
29. Siegal, D.M. et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N. Engl. J. Med. 373, 2413-2424 (2015).
30. Bajaj, M.S., Birktoft, J.J., Steer, S.A. & Bajaj, S.P. Structure and biology of tissue factor pathway inhibitor. Thromb. Haemost. 86, 959-972 (2001).
31. Huntington, J.A. Thrombin inhibition by the serpins. J. Thromb. Haemost. 11 (suppl. 1), 254-264 (2013).
32. Toso, R., Zhu, H. & Camire, R.M. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly. J. Biol. Chem. 283, 18627-18635 (2008).
33. Bunce, M.W., Toso, R. & Camire, R.M. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood 117, 290-298 (2011).
34. Ivanciu, L. et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat. Biotechnol. 29, 1028-1033 (2011).
35. Bode, W. et al. The refined 1.9 Å crystal structure of human α-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 8, 3467-3475 (1989).
36. Samama, M.M. et al. Laboratory assessment of rivaroxaban: a review. Thromb. J. 11, 11 (2013).
37. Samama, M.M. & Guinet, C. Laboratory assessment of new anticoagulants. Clin. Chem. Lab. Med. 49, 761-772 (2011).
38. Mueck, W., Stampfuss, J., Kubitza, D. & Becka, M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin. Pharmacokinet. 53, 1-16 (2014).
39. Turecek, P.L., Váradi, K., Gritsch, H. & Schwarz, H.P. FEIBA: mode of action. Haemophilia 10 (suppl. 2), 3-9 (2004).
40. Whinna, H.C. Overview of murine thrombosis models. Thromb. Res. 122 (suppl. 1), S64-S69 (2008).
41. Scaglione, F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin. Pharmacokinet. 52, 69-82 (2013).
42. Gitel, S.N., Medina, V.M. & Wessler, S. Inhibition of human activated Factor X by antithrombin III and α1-proteinase inhibitor in human plasma. J. Biol. Chem. 259, 6890-6895 (1984).
43. Olson, S.T. et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J. Biol. Chem. 267, 12528-12538 (1992).
44. Conard, J., Brosstad, F., Lie Larsen, M., Samama, M. & Abildgaard, U. Molar antithrombin concentration in normal human plasma. Haemostasis 13, 363-368 (1983).
45. Izaguirre, G. et al. Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease. J. Biol. Chem. 289, 34049-34064 (2014).
46. Perzborn, E. et al. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler. Thromb. Vasc. Biol. 30, 376-381 (2010).
47. Craig, P.A., Olson, S.T. & Shore, J.D. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Characterization of assembly, product formation and heparin dissociation steps in the factor Xa reaction. J. Biol. Chem. 264, 5452-5461 (1989).
48. Olson, S.T. & Shore, J.D. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. The reaction step limiting heparin turnover in thrombin neutralization. J. Biol. Chem. 261, 13151-13159 (1986).
49. Esmon, C.T. & Owen, W.G. The discovery of thrombomodulin. J. Thromb. Haemost. 2, 209-213 (2004).
50. Smith, S.A. & Morrissey, J.H. Polyphosphate as a general procoagulant agent. J. Thromb. Haemost. 6, 1750-1756 (2008).
51. Weiler-Guettler, H. et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J. Clin. Invest. 101, 19 83-1991 (1998).
52. Neyman, M., Gewirtz, J. & Poncz, M. Analysis of the spatial and temporal characteristics of platelet-delivered factor-VIII-based clots. Blood 112, 1101-1108 (2008).
53. Kisiel, W., Hermodson, M.A. & Davie, E.W. Factor X activating enzyme from Russell's viper venom: isolation and characterization. Biochemistry 15, 4901-4906 (1976).
54. Larson, P.J. et al. Structure-function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles. Biochemistry 37, 5029-5038 (1998).
55. Camire, R.M., Larson, P.J., Stafford, D.W. & High, K.A. Enhanced γ-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide. Biochemistry 39, 14322-14329 (2000).
56. Morita, T. & Jackson, C.M. Preparation and properties of derivatives of bovine factor X and factor Xa from which the γ-carboxyglutamic-acid-containing domain has been removed. J. Biol. Chem. 261, 4015-4023 (1986).
57. Toso, R. & Camire, R.M. Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized. J. Biol. Chem. 279, 21643-21650 (2004).
58. Lu, G., Broze, G.J. Jr. & Krishnaswamy, S. Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III. J. Biol. Chem. 279, 17241-17249 (2004).
59. Parry, T.J. et al. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagul. Fibrinolysis 22, 720-726 (2011).
60. Falati, S., Gross, P., Merrill-Skoloff, G., Furie, B.C. & Furie, B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat. Med. 8, 1175-1181 (2002).
61. Schlachterman, A. et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J. Thromb. Haemost. 3, 2730-2737 (2005).
62. Lin, H.F., Maeda, N., Smithies, O., Straight, D.L. & Stafford, D.W. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 90, 3962-3966 (1997).
63. Ivanciu, L., Krishnaswamy, S. & Camire, R.M. New insights into the spatiotemporal localization of prothrombinase in vivo. Blood 124, 1705-1714 (2014).
64. Green, R.A., LaFollette, K.A. & Greig, B. Use of hexadimethrine bromide as a heparin-neutralizing agent in canine plasma. Am. J. Vet. Res. 48, 496-498 (1987).